Anti-inflammatory activity of curcumin-loaded solid lipid nanoparticles in IL-1β transgenic mice subjected to the lipopolysaccharide-induced sepsis

Biomaterials

Volumn 53, Issue , 2015, Pages 475-483

  Wang, Jiao ^a   Wang, Haoyue ^a,b   Zhu, Rongrong ^a   Liu, Qiang ^a   Fei, Jian ^a,b   Wang, Shilong ^a  

^a TONGJI UNIVERSITY   (China)

^b Shanghai Research Center for Model Organisms   (China)

Author keywords

Curcumin; IL 1 ; Lipopolysaccharide; Sepsis; Solid lipid nanoparticles; TLR4

Indexed keywords

BIOCHEMISTRY; MAMMALS; NANOPARTICLES;

CURCUMIN; LIPOPOLYSACCHARIDES; SEPSIS; SOLID LIPID NANOPARTICLE (SLN); TLR4;

PLANTS (BOTANY);

CURCUMIN; DEXAMETHASONE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; SOLID LIPID NANOPARTICLE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; AUTACOID; CYTOKINE; DRUG CARRIER; LIPID; LIPOPOLYSACCHARIDE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULOSCLEROSIS; HYDRODYNAMICS; INNATE IMMUNITY; KIDNEY TUBULE DISORDER; LIVER NECROSIS; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ZETA POTENTIAL; ANIMAL; BLOOD; CHEMICALLY INDUCED; CHEMISTRY; GENETICS; METABOLISM; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CURCUMIN; CYTOKINES; DRUG CARRIERS; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; LIPIDS; LIPOPOLYSACCHARIDES; MICE; MICE, TRANSGENIC; NANOPARTICLES; PROMOTER REGIONS, GENETIC; SEPSIS; SIGNAL TRANSDUCTION;

EID: 84927940418     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.02.116     Document Type: Article

References (64)

1. Cohen J. The immunopathogenesis of sepsis. Nature 2002, 420:885-891.
2. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. NEngl J Med 2003, 348:138-150.
3. Wheeler D.S. Death to sepsis: targeting apoptosis pathways in sepsis. Crit Care 2009, 13:1010.
4. Dellinger R.P., Levy M.M., Carlet J.M., Bion J., Parker M.M., Jaeschke R., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327.
5. Chowdhury P., Sacks S.H., Sheerin N.S. Toll-like receptors TLR2 and TLR4 initiate the innate immune response of the renal tubular epithelium to bacterial products. Clin Exp Immunol 2006, 145:346-356.
6. Shi J., Zhao Y., Wang Y., Gao W., Ding J., Li P., et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 2014, 514:187-192.
7. Salomao R., Brunialti M.K., Rapozo M.M., Baggio-Zappia G.L., Galanos C., Freudenberg M. Bacterial sensing, cell signaling, and modulation of the immune response during sepsis. Shock 2012, 38:227-242.
8. Maheshwari R.K., Singh A.K., Gaddipati J., Srimal R.C. Multiple biological activities of curcumin: a short review. Life Sci 2006, 78:2081-2087.
9. Basnet P., Skalko-Basnet N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules 2011, 16:4567-4598.
10. Aggarwal B.B., Harikumar K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009, 41:40-59.
11. Sompamit K., Kukongviriyapan U., Nakmareong S., Pannangpetch P., Kukongviriyapan V. Curcumin improves vascular function and alleviates oxidative stress in non-lethal lipopolysaccharide-inducedendotoxaemia in mice. Eur J Pharmacol 2009, 616:192-199.
12. Poylin V., Fareed M.U., O'Neal P., Alamdari N., Reilly N., Menconi M., et al. The NF-kappaB inhibitor curcumin blocks sepsis-induced muscle proteolysis. Mediat Inflamm 2008, 2008:317851.
13. Xiao X., Yang M., Sun D., Sun S. Curcumin protects against sepsis-induced acute lung injury in rats. JSurg Res 2012, 176:e31-e39.
14. Lukita-Atmadja W., Ito Y., Baker G.L., McCuskey R.S. Effect of curcuminoids as anti-inflammatory agents on the hepatic microvascular response to endotoxin. Shock 2002, 17:399-403.
15. Yang C., Wu K., Li S.H., You Q. Protective effect of curcumin against cardiac dysfunction in sepsis rats. Pharm Biol 2013, 51:482-487.
16. Gupta S.C., Prasad S., Kim J.H., Patchva S., Webb L.J., Priyadarsini I.K., et al. Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep 2011, 28:1937-1955.
17. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol Pharm 2007, 4:807-818.
18. Burgos-Morón E., Calderón-Montaño J.M., Salvador J., Robles A., López-Lázaro M. The dark side of curcumin. Int J Cancer 2010, 126:1771-1775.
19. Mohanty C., Sahoo S.K. The invitro stability and invivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials 2010, 31:6597-6611.
20. Hou D., Xie C., Huang K., Zhu C. The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 2003, 24:1781-1785.
21. Mehnert W., Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001, 47:165-196.
22. Gao Y., Gu W., Chen L., Xu Z., Li Y. The role of daidzein-loaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseases. Biomaterials 2008, 29:4129-4136.
23. Xu Z., Chen L., Gu W., Gao Y., Lin L., Zhang Z., et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 2009, 30:226-232.
24. Kuo Y.C., Liang C.T. Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials 2011, 32:3340-3350.
25. Wang W., Zhu R., Xie Q., Li A., Xiao Y., Li K., et al. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int J Nanomedicine 2012, 7:3667-3677.
26. Wang J., Zhu R., Sun D., Sun X., Geng Z., Liu H., et al. Intracellular uptake of etoposide-loaded solid lipid nanoparticles induces an enhancing inhibitory effect on gastric cancer through mitochondria-mediated apoptosis pathway. JBiomed Nanotechnol 2015, 11:403-415.
27. Li L., Fei Z., Ren J., Sun R., Liu Z., Sheng Z., et al. Functional imaging of interleukin 1 beta expression in inflammatory process using bioluminescence imaging in transgenic mice. BMC Immunol 2008, 9:49.
28. Li L., Liu Z., Yang X., Yan H., Bao S., Fei J. Bioluminescence imaging for IL-1β expression in experimental colitis. JInflamm 2013, 10:16.
29. Li H., Zhao X., Ma Y., Zhai G., Li L., Lou H. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. JControl Release 2009, 133:238-244.
30. Liu H., Wise S.G., Rnjak-Kovacina J., Kaplan D.L., Bilek M.M., Weiss A.S., et al. Biocompatibility of silk-tropoelastin protein polymers. Biomaterials 2014, 35:5138-5147.
31. Tavakoli N.N., Harris A.K., Sullivan D.R., Hambly B.D., Bao S. Interferon-γ deficiency reduces neointimal formation in a model of endoluminal endothelial injury combined with atherogenic diet. Int J Mol Med 2012, 30:545-552.
32. Li A., Qin L.L., Zhu D., Zhu R.R., Sun J., Wang S.L. Signalling pathways involved in the activation of dendritic cells by layered double hydroxide nanoparticles. Biomaterials 2010, 31:748-756.
33. 2 at LDH nanoparticles as an adjuvant. Biomaterials 2014, 35:466-478.
34. Morishige T., Yoshioka Y., Inakura H., Tanabe A., Yao X., Narimatsu S., et al. The effect of surface modification of amorphous silica particles on NLRP3 inflammasome mediated IL-1beta production, ROS production and endosomal rupture. Biomaterials 2010, 31:6833-6842.
35. Cannon J.G., Friedberg J.S., Gelfand J.A., Tompkins R.G., Burke J.F., Dinarello C.A. Circulating interleukin-1 beta and tumor necrosis factor-alpha concentrations after burn injury in humans. Crit Care Med 1992, 20:1414-1419.
36. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
37. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
38. Anonymous Focus on sepsis. Nat Med 2012, 18:997.
39. O'Brien T.F. Global surveillance of antibiotic resistance. NEngl J Med 1992, 326:339-340.
40. Stoll B.J., Hansen N., Fanaroff A.A., Wright L.L., Carlo W.A., Ehrenkranz R.A., et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002, 110:285-291.
41. Andrews P., Azoulay E., Antonelli M., Brochard L., Brun-Buisson C., Dobb G., et al. Year in review in intensive care medicine, 2005. II. Infection and sepsis, ventilator associated pneumonia, ethics, hematology and hemostasis, ICU organization and scoring, brain injury. Intensive Care Med 2006, 32:380-390.
42. Singh S. From exotic spice to modern drug?. Cell 2007, 130:765-768.
43. Srivastava R., Dikshit M., Srimal R.C., Dhawan B.N. Anti-thrombotic effect of curcumin. Thromb Res 1985, 40:413-417.
44. Shin S.K., Ha T.Y., McGregor R.A., Choi M.S. Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Mol Nutr Food Res 2011, 55:1829-1840.
45. Asai A., Miyazawa T. Dietary curcuminoids prevent high-fat diet-induced lipid accumulation in rat liver and epididymal adipose tissue. JNutr 2001, 131:2932-2935.
46. Baum L., Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. JAlzheimers Dis 2004, 6:367-377.
47. Hanai H., Sugimoto K. Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr Pharm Des 2009, 15:2087-2094.
48. Aggarwal B.B., Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 2009, 30:85-94.
49. Naksuriya O., Okonogi S., Schiffelers R.M., Hennink W.E. Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials 2014, 3:3365-3383.
50. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011, 63:136-151.
51. Kim J., Kim P.H., Kim S.W., Yun C.O. Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials. Biomaterials 2012, 33:1838-1850.
52. Strehle E.M. Long-term management of children with neuromuscular disorders. JPediatr (Rio J) 2009, 85:379-384.
53. Netea M.G., van der Meer J.W., van Deuren M., Kullberg B.J. Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing?. Trends Immunol 2003, 24:254-258.
54. Ulloa L., Tracey K.J. The "cytokine profile": a code for sepsis. Trends Mol Med 2005, 11:56-63.
55. Chen X., Wang Y., Luo H., Luo Z., Liu L., Xu W., et al. Ulinastatin reduces urinary sepsis-related inflammation by upregulating IL-10 and downregulating TNF-α levels. Mol Med Rep 2013, 8:29-34.
56. Drazan K.E., Wu L., Bullington D., Shaked A. Viral IL-10 gene therapy inhibits TNF-alpha and IL-1 beta, not IL-6, in the newborn endotoxemic mouse. JPediatr Surg 1996, 31:411-414.
57. Scumpia P.O., Moldawer L.L. Biology of interleukin-10 and its regulatory roles in sepsis syndromes. Crit Care Med 2005, 33:S468-S471.
58. Gower R.M., Boehler R.M., Azarin S.M., Ricci C.F., Leonard J.N., Shea L.D. Modulation of leukocyte infiltration and phenotype in microporous tissue engineering scaffolds via vector induced IL-10 expression. Biomaterials 2014, 35:2024-2031.
59. Goldstein B., Giroir B., Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005, 6:2-8.
60. Rhee S.H., Hwang D. Murine TOLL-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF kappa B and expression of the inducible cyclooxygenase. JBiol Chem 2000, 275:34035-34040.
61. Spiller S., Elson G., Ferstl R., Dreher S., Mueller T., Freudenberg M., et al. TLR4-induced IFN-gamma production increases TLR2 sensitivity and drives Gram-negative sepsis in mice. JExp Med 2008, 205:1747-1754.
62. Gadjeva M., Tomczak M.F., Zhang M., Wang Y.Y., Dull K., Rogers A.B., et al. Arole for NF-kappa B subunits p50 and p65 in the inhibition of lipopolysaccharide-induced shock. JImmunol 2004, 173:5786-5793.
63. Buchanan F.F., Myles P.S., Cicuttini F. Patient sex and its influence on general anaesthesia. Anaesth Intensive Care 2009, 37:207-218.
64. Jarugula V., Yeh C.M., Howard D., Bush C., Keefe D.L., Dole W.P. Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren. JClin Pharmacol 2010, 50:1358-1366.